{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:03:40Z","timestamp":1761415420407,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.hlc.2018.02.013","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T17:24:16Z","timestamp":1519925056000},"page":"911-916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Resistant Hypertension: Which Agent?"],"prefix":"10.1016","volume":"27","author":[{"given":"Hamish C.G.","family":"Prosser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-2062","authenticated-orcid":false,"given":"Omar","family":"Azzam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus P.","family":"Schlaich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2018.02.013_bib0005","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.02.013_bib0010","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.02.013_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/HYPERTENSIONAHA.117.08929","article-title":"Resistant hypertension: an update of experimental and clinical findings","volume":"70","author":"Cai","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.hlc.2018.02.013_bib0020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.hlc.2018.02.013_bib0025","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2018.02.013_bib0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"New Engl J Med"},{"key":"10.1016\/j.hlc.2018.02.013_bib0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/nep.12475","article-title":"Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy","volume":"20","author":"Verdalles","year":"2015","journal-title":"Nephrology"},{"key":"10.1016\/j.hlc.2018.02.013_bib0040","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.hlc.2018.02.013_bib0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jash.2016.02.015","article-title":"Evidence for a critical role of the sympathetic nervous system in hypertension","volume":"10","author":"Grassi","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.hlc.2018.02.013_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/541689","article-title":"Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study","volume":"2013","author":"Chazova","year":"2013","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.hlc.2018.02.013_bib0055","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1097\/00004872-199715011-00007","article-title":"The use of moxonidine in the treatment of hypertension","volume":"15","author":"Prichard","year":"1997","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.hlc.2018.02.013_bib0060","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-200666040-00006","article-title":"Moxonidine: a review of its use in essential hypertension","volume":"66","author":"Fenton","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.hlc.2018.02.013_bib0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.107.737957","article-title":"Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"118","author":"Chapman","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2018.02.013_bib0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/08037050902843726","article-title":"Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension","volume":"18","author":"Ceral","year":"2009","journal-title":"Blood Press"},{"key":"10.1016\/j.hlc.2018.02.013_bib0075","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2018.02.013_bib0080","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/jch.12847","article-title":"Minoxidil for treatment of resistant hypertension in chronic kidney disease\u2014a retrospective cohort analysis","volume":"18","author":"Mundt","year":"2016","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.hlc.2018.02.013_bib0085","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/HJH.0b013e32809c2cc9","article-title":"Usefulness of the vasodilator minoxidil in resistant hypertension","volume":"25","author":"Black","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.hlc.2018.02.013_bib0090","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.clinthera.2016.08.015","article-title":"Device therapies for resistant hypertension","volume":"38","author":"Hering","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.hlc.2018.02.013_bib0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurheartj\/ehu441","article-title":"Predictors of blood pressure response in the SYMPLICITY HTN-3 trial","volume":"36","author":"Kandzari","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2018.02.013_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial","author":"Townsend","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2018.02.013_bib0105","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.117.10290","article-title":"Renal denervation after the SPYRAL HTN-OFF MED trial: putting a complex study into context","author":"Schlaich","year":"2017","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.hlc.2018.02.013_bib0110","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ajh\/hpx033","article-title":"Renal sympathetic denervation: a viable option for treating resistant hypertension","volume":"30","author":"Schlaich","year":"2017","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.hlc.2018.02.013_bib0115","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/HYPERTENSIONAHA.117.09086","article-title":"Sustained reduction of blood pressure with baroreceptor activation therapy: results of the 6-year open follow-up","volume":"69","author":"de Leeuw","year":"2017","journal-title":"Hypertension"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950618300763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950618300763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:59:25Z","timestamp":1761415165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950618300763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1443950618300763"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2018.02.013","relation":{},"ISSN":["1443-9506"],"issn-type":[{"type":"print","value":"1443-9506"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistant Hypertension: Which Agent?","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2018.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}